Charles River Laboratories International, Inc. (CRL): Total Assets
$7.14B
As of 2025-12-27
$7.53B
As of 2026-06-27
-2.1%
3-year compound annual growth
+5.4%
5-year compound annual growth
+13.2%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-27 | $7.14B | -5.2% | 2026-02-18, Balance as of period end |
| 2024-12-28 | $7.53B | -8.1% | 2026-02-18, Balance as of period end |
| 2023-12-30 | $8.20B | +7.8% | 2025-02-19, Balance as of period end |
| 2022-12-31 | $7.60B | +8.2% | 2024-02-14, Balance as of period end |
| 2021-12-25 | $7.02B | +27.9% | 2023-02-22, Balance as of period end |
| 2020-12-26 | $5.49B | +17.0% | 2022-02-16, Balance as of period end |
| 2019-12-28 | $4.69B | +21.7% | 2021-02-17, Balance as of period end |
| 2018-12-29 | $3.86B | +31.6% | 2020-02-11, Balance as of period end |
| 2017-12-30 | $2.93B | +8.0% | 2019-02-13, Balance as of period end |
| 2016-12-31 | $2.71B | +31.1% | 2018-02-13, Balance as of period end |
| 2015-12-26 | $2.07B | +10.6% | 2017-02-14, Balance as of period end |
| 2014-12-27 | $1.87B | +14.6% | 2016-02-12, Balance as of period end |
| 2013-12-28 | $1.63B | +2.9% | 2015-02-17, Balance as of period end |
| 2012-12-29 | $1.59B | +1.8% | 2014-02-25, Balance as of period end |
| 2011-12-31 | $1.56B | -10.1% | 2013-02-27, Balance as of period end |
| 2010-12-25 | $1.73B | -21.4% | 2012-02-27, Balance as of period end |
| 2009-12-26 | $2.20B | n/a | 2011-02-23, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Charles River Laboratories International, Inc. (CRL) | 2025-12-27 | $7.14B | -5.2% |
| Incyte Corp (INCY) | 2025-12-31 | $6.96B | +27.8% |
| Medpace Holdings, Inc. (MEDP) | 2025-12-31 | $1.98B | -6.0% |
| Icon PLC (ICLR) | 2025-12-31 | $16.27B | -2.2% |
| Iqvia Holdings Inc. (IQV) | 2025-12-31 | $29.94B | +11.3% |
| NRC Health (NRC) | 2025-12-31 | $134.88M | +1.8% |
| MaxCyte, Inc. (MXCT) | 2025-12-31 | $202.51M | -15.4% |
| OmniAb, Inc. (OABI) | 2025-12-31 | $300.91M | -7.6% |
| Foxo Technologies Inc. (FOXO) | 2025-12-31 | $44.58M | +6.9% |
Compare CRL, INCY, MEDP, ICLR side by side · Screen every company in Services-Commercial Physical & Biological Research ↗